MannKind Corporation (MNKD)

1.62
0.07 4.20
NASDAQ
Prev Close 1.56
Open 1.56
Day Low/High 1.55 / 1.63
52 Wk Low/High 0.80 / 2.48
Volume 1.15M
Exchange NASDAQ
Shares Outstanding 213.14B
Market Cap 349.55M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Insulin Drug Offers Hope for MannKind

Insulin Drug Offers Hope for MannKind

The stock has taken a beating, but users of Afrezza are loyal to the drug.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 tweets by TheStreet's Adam Feuerstein kept us informed and entertained. From an unexpected twist on New Year's day with MannKind to J.P. Morgan's Healthcare conference to Bristol-Myers Squibb's oops!

What's Ahead for the Week: Can FedEx Deliver a Strong Quarter?

What's Ahead for the Week: Can FedEx Deliver a Strong Quarter?

In 'What's Ahead on Wall Street' for the week of March 14, we have a mix of both earnings and economic data.

MannKind Investors Should Have Seen the Writing on the Wall

MannKind Investors Should Have Seen the Writing on the Wall

Shareholders should have been running from the drugmaker long before Tuesday's news that partner Sanofi was leaving first.

Is This One Giant Lurch for MannKind?

Meet the new (and likely temporary, 90-year-old) boss, same as the old boss.

Mannkind downgraded at RBC

Challenge to Readers: Value These 4 Stocks

Challenge to Readers: Value These 4 Stocks

Can a 'fair value' really be determined for the unprofitable Tesla, SunEdison, Plug Power and Mannkind?

Mannkind downgraded at Piper

Building a Sweet 16 Portfolio, Part 2

Building a Sweet 16 Portfolio, Part 2

A little of this, a little of that to create a nice yield.

Building a Sweet 16 Portfolio, Part 1

Selection of stocks is tailor made for investor, given market parameters.

Mannkind downgraded at JP Morgan

A Little Faith in MannKind

A Little Faith in MannKind

After an overly aggressive downgrade, is this a chance to buy?

EYES Has It

Second Sight's IPO was well received.

Fitz Bits: Do Not Try to Top-Tick

Fitz Bits: Do Not Try to Top-Tick

For now, just let the market do the heavy lifting for you.

Mannkind upgraded at Piper

Jim Cramer on Mannkind, Visa, FireEye and Linn Energy's Dividend

Jim Cramer on Mannkind, Visa, FireEye and Linn Energy's Dividend

TheStreet's Jim Cramer is asked for advice on Mannkind, which has doubled in value after an FDA panel recommended approval of its insulin drug Afreeza.

MannKind Catches Fire While Zuckerberg, "Frozen" Stay Hot

MannKind Catches Fire While Zuckerberg, "Frozen" Stay Hot

Disney's 'Frozen' skated its way into history this week, becoming the highest-grossing animated movie ever with a total worldwide gross of $1.07 billion and counting.

Jim Cramer is Neutral on Mannkind's Afrezza Inhaled Insulin

Jim Cramer is Neutral on Mannkind's Afrezza Inhaled Insulin

TheStreet's Jim Cramer says he is completely neutral on Mannkind and sometimes it's better to admit you don't know where something is going.

Jobs Data, More GM Testimony and Mannkind Gets a Nod

Jobs Data, More GM Testimony and Mannkind Gets a Nod

ADP private payrolls data missed expectations for March, but the revision upward of February's number seemed to slightly satisfy traders.

Day Ahead: Riding the Wave Higher

Day Ahead: Riding the Wave Higher

Futures poised to extend gains; MannKind shares double.

Mannkind downgraded at BofA/Merrill

Mannkind downgraded at BofA/Merrill